valsartan + reteplase

Valsartan + reteplase is a combination of two pharmaceutical agents with distinct mechanisms of action, potentially used together in the management of acute cardiovascular events. Valsartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension, heart failure, and to reduce cardiovascular risk after myocardial infarction. It works by blocking angiotensin II from binding to its receptor, leading to vasodilation and reduced blood pressure[2][8]. Reteplase is a recombinant tissue plasminogen activator (tPA) used as a thrombolytic agent in the emergency treatment of acute myocardial infarction. It acts by catalyzing the conversion of plasminogen to plasmin, which degrades fibrin clots and restores blood flow in occluded arteries[1][3][5]. The combination may be considered in clinical scenarios where both blood pressure control and rapid clot dissolution are required.

Other names

none